![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » THERMOGENESIS CORP. SIGNS AGREEMENT WITH BIOMET BIOLOGICS, INC. TO PRODUCE INTRA-OPERATIVE AUTOLOGOUS FIBRIN SEALANT
THERMOGENESIS CORP. SIGNS AGREEMENT WITH BIOMET BIOLOGICS, INC. TO PRODUCE INTRA-OPERATIVE AUTOLOGOUS FIBRIN SEALANT
August 3, 2006
ThermoGenesis Corp. announced that the Company entered into a development, license and supply agreement with Biomet Biologics, Inc., a wholly owned subsidiary of Biomet, Inc. Biomet Biologics plans to combine ThermoGenesis' protein harvesting technology with its currently offered and future autologous therapies to manufacture autologous fibrin sealant in a peri-operative setting. The product will feature
a fibrinogen harvesting disposable in combination with Biomet Biologics' Clotalyst
System that can produce fibrin sealant from a patient's own blood in less than
30 minutes. Fibrin sealant is an adhesive gel used by surgeons to stop bleeding
and bond tissue.
Yahoo
News
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct